#USA #Pittsburgh #Pacira BioSciences #Exparel #Viatris

Viatris' Acquisition of Pacira BioSciences

Viatris Inc. has officially announced its decision to acquire Pacira BioSciences, joining forces to enhance its innovative medicines strategy and establish a stronger foothold in the non-opioid pain therapy market. This acquisition marks a significant milestone for Viatris as it seeks to broaden its portfolio and improve healthcare solutions for patients.

Strategic Rationale for the Acquisition

In a definitive agreement, Viatris will acquire all outstanding shares of Pacira at a cash price of $36.50 per share, totaling an equity value of approximately $1.65 billion. Pacira, a well-known leader in non-opioid pain management therapies, is responsible for two established products in the U.S. market: EXPAREL® and ZILRETTA®. These high-margin medicines present an opportunity for Viatris to leverage its existing market infrastructure and maximize product reach effectively.

PACIRA's EXPAREL is a long-acting local anesthetic, specifically designed to manage postsurgical pain, while ZILRETTA serves as an extended-release intra-articular injection aimed at easing osteoarthritis knee pain. Given that both products have demonstrated strong revenue generation—approximately $746 million in total revenue and $177 million in adjusted EBITDA in the past year—this acquisition is set to bring immediate financial benefits.

Scott A. Smith, CEO of Viatris, highlighted the importance of this acquisition: "The pending acquisition of Pacira BioSciences is an essential step towards advancing our strategy to develop innovative medicines. We believe that having EXPAREL and ZILRETTA in our portfolio will position us as a leader in non-opioid pain management therapies, addressing a critical need for more effective treatment options in this area."

Enhancing Capabilities and Market Reach

With the integration of Pacira, Viatris expects to enhance its U.S. innovative medicines capabilities, market access, medical affairs, and global research and development functions. These enhancements will be crucial as the demand for non-opioid alternatives continues to rise among patients and healthcare providers seeking safer pain management solutions.

Paul Campbell, Interim CFO of Viatris, elucidated on the financial strategy behind the deal: "We anticipate that the acquisition will be immediately accretive to our financial metrics and will be primarily funded through excess cash, with some reliance on short-term borrowings. This approach will have minimal impact on our gross leverage ratio, preserving our financial flexibility while creating synergies that drive further value."

The Future of Non-Opioid Pain Therapies

As Viatris prepares to close this transaction by the end of 2026, the importance of non-opioid pain management therapies becomes increasingly evident. Frank D. Lee, CEO of Pacira, expressed confidence in the merger: "Our mission has always been to deliver innovative, non-opioid pain therapies that transform the lives of patients. By combining our resources with Viatris, we can amplify our reach and impact, ensuring that more patients gain access to effective pain management solutions."

The proposed transaction must meet customary closing conditions, which include securing a majority of Pacira's outstanding shares and meeting regulatory requirements. Once completed, Pacira will operate as a wholly owned subsidiary of Viatris, with its common stock ceasing to be traded on the Nasdaq Global Select Market.

Conclusion

Viatris’ acquisition of Pacira BioSciences is designed to align with their vision to empower healthier lives globally. By enhancing its product lineup with innovative offerings in pain management, Viatris is poised to not only retain a competitive edge in the healthcare sector but also transform the landscape of treatment options for those affected by pain, ultimately fostering a brighter future for patient care.